Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, has announced its participation in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum brings together experts in nasal drug development, providing a platform for Silo to discuss its ongoing work with SPC-15, a therapeutic candidate employing a nose-to-brain delivery approach for the treatment of post-traumatic stress disorder (PTSD).
The company's CEO, Eric Weisblum, emphasized the value of engaging with peers in the field as Silo continues to advance SPC-15. Preclinical data for SPC-15 have shown that the formulation and device meet predefined specifications for assay, impurities, pH, and microbiological quality through nine months. Additionally, six-month accelerated stability data were consistent and aligned with long-term data, indicating the product's robustness.
This participation comes at a critical time for Silo Pharma, which is diversifying its pipeline to address underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Among its key programs are SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's research collaborations with leading universities and laboratories support its innovative approach.
The nasal delivery route is of particular interest in CNS drug development because it bypasses the blood-brain barrier, offering a direct pathway for therapeutics to reach the brain. SPC-15's nose-to-brain strategy could potentially improve the efficacy and reduce systemic side effects compared to traditional delivery methods. The stability data presented at the forum could provide evidence of the product's viability for future clinical trials.
According to the company, the forum presents an opportunity to network with key opinion leaders and potential partners in nasal drug delivery. Silo Pharma's commitment to this therapeutic area is underscored by its participation in such industry events, which are crucial for gaining insights and fostering collaborations.
Investors and industry observers will be watching for further updates from Silo Pharma as it progresses its pipeline. The company's latest news and updates are available in its newsroom at https://ibn.fm/SILO. The full press release about the forum participation can be accessed at https://ibn.fm/Dy4qf.
The IPAC-RS forum is a recognized venue for discussing regulatory, scientific, and technical aspects of inhaled and nasal drug products. Silo's involvement highlights its dedication to meeting regulatory standards and its proactive approach in engaging with the scientific community.
As Silo Pharma continues to develop its therapeutic portfolio, the company's focus on innovative drug delivery systems remains a cornerstone of its strategy. The positive stability data for SPC-15 could pave the way for future regulatory filings and clinical development, potentially bringing new treatment options to patients suffering from PTSD and other CNS disorders.
